Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression

Eur J Clin Invest. 2008 Jun;38(6):447-55. doi: 10.1111/j.1365-2362.2008.01950.x. Epub 2008 Apr 24.

Abstract

Background: Basophilic crisis and eosinophilia are well recognized features of advanced chronic myeloid leukaemia. In other myeloid neoplasms, however, transformation with marked basophilia and eosinophilia is considered unusual.

Design: We examined the long-term follow-up of 322 patients with de novo myelodysplastic syndromes (MDS) to define the frequency of basophilic, eosinophilic and mixed lineage (basophilic and eosinophilic) transformation.

Results: Of all patients, only one developed mixed lineage crisis (>or= 20% basophils and >or= 20% eosinophils). In this patient, who initially suffered from chronic myelomonocytic leukaemia, basophils increased to 48% and eosinophils up to 31% at the time of progression. Mixed lineage crisis was not accompanied by an increase in blast cells or organomegaly. The presence of BCR/ABL and other relevant fusion gene products (FIP1L1/PDGFRA, AML1/ETO, PML/RAR alpha, CBF beta/MYH11) were excluded by PCR. Myelomastocytic transformation/myelomastocytic leukaemia and primary mast cell disease were excluded by histology, KIT mutation analysis, electron microscopy and immunophenotyping. Basophils were thus found to be CD123+, CD203c+, BB1+, KIT- cells, and to express a functional IgE-receptor. Among the other patients with MDS examined, 4(1.2%) were found to have marked basophilia (>or= 20%) and 7(2.1%) were found to have massive eosinophilia ( >or= 20%), whereas mixed-lineage crisis was detected in none of them.

Conclusions: Mixed basophil/eosinophil crisis may develop in patients with MDS but is an extremely rare event.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Basophils / immunology*
  • Disease Progression
  • Eosinophils / immunology*
  • Female
  • Flow Cytometry
  • Follow-Up Studies
  • Histamine Release
  • Humans
  • Hydroxyurea / therapeutic use
  • Immunohistochemistry
  • Immunophenotyping
  • Leukemia, Myelomonocytic, Chronic / drug therapy
  • Leukemia, Myelomonocytic, Chronic / immunology*
  • Leukemia, Myelomonocytic, Chronic / pathology
  • Leukocyte Count
  • Male
  • Microscopy, Electron
  • Middle Aged
  • Receptors, IgE / analysis
  • Retrospective Studies

Substances

  • Antineoplastic Agents
  • Receptors, IgE
  • Hydroxyurea